The "Lowering Drug Costs for American Families Act" proposes significant changes to prescription drug pricing and consumer costs across various health insurance markets. A primary goal is to expand the existing drug price negotiation program under Medicare, increasing the number of drugs subject to negotiation from 20 to 50. Crucially, the bill extends the application of these negotiated "maximum fair prices" to individuals covered by group health plans and individual market health insurance, provided these plans voluntarily agree to participate.

To further enhance price control, the legislation mandates that the Secretary consider the average international market price of a drug when conducting negotiations, using data from countries like Australia, Canada, France, Germany, Japan, and the United Kingdom. This aims to benchmark U.S. drug prices against those in other developed nations. Additionally, the bill repeals certain changes made to the drug price negotiation program by Public Law 119-21, restoring prior provisions.

Beyond negotiation, the bill seeks to apply prescription drug inflation rebates, currently limited to Medicare, to drugs furnished in the commercial market. This means drug manufacturers would owe rebates if their drug prices increase faster than inflation for commercial sales, similar to existing Medicare rules. The bill also refines the methodology for calculating these rebates, particularly for Part D drugs, by adjusting how units are counted and excluding those already subject to other rebates or discounts.

A key consumer protection measure is the establishment of out-of-pocket spending limits for prescription drugs under private health insurance, effective for plan years beginning in 2027. This includes an overall annual out-of-pocket limit for all cost-sharing, tied to existing Affordable Care Act limits, and a specific annual cap of $2,000 for prescription drug expenses for self-only coverage, with double that amount for other coverage. These limits will be adjusted annually for inflation.

Finally, the bill introduces specific requirements for insulin cost-sharing. Starting in 2027, group health plans and health insurance issuers must cover selected insulin products without a deductible. Cost-sharing for these products will be capped at the lesser of $35 per 30-day supply or 25% of the negotiated price, and these payments will count towards an individual's overall deductible and out-of-pocket maximums.